Following enrolment into plasmaMATCH, patients had a blood sample drawn which underwent prospective ctDNA testing for hotspot mutations in
PIK3CA, ESR1, HER2 and
AKT1 (Supplementary Fig.
1b and Supplementary Table
4, and methodology previously published
44 ). DNA was extracted from screening plasma using the automated
QiaSymphony platform (Qiagen, Hilden). DNA was quantified by Qubit (Thermo Scientific) before being combined with singleplex or multiplex droplet digital PCR (ddPCR) assays targeting hotspot mutations
44 (Supplementary Table
4), supermix and nuclease free water. The samples were partitioned into droplets using an
Automated Droplet Generator (Bio-Rad, Pleasanton) before undergoing 40 cycles of PCR on a thermal cycler. Results were analysed on a
QX200 Digital Reader (Bio-Rad, Pleasanton). ddPCR assays were considered positive with a minimum of two positive FAM droplets (mutant) per reaction. Poisson probability was used to calculate allele frequency (AF).
Kingston B., Cutts R.J., Bye H., Beaney M., Walsh-Crestani G., Hrebien S., Swift C., Kilburn L.S., Kernaghan S., Moretti L., Wilkinson K., Wardley A.M., Macpherson I.R., Baird R.D., Roylance R., Reis-Filho J.S., Hubank M., Faull I., Banks K.C., Lanman R.B., Garcia-Murillas I., Bliss J.M., Ring A, & Turner N.C. (2021). Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 12, 2423.